BACKGROUND: Afatinib is an oral, irreversible ErbB family blocker indicated for first-line treatment of metastatic non-small cell lung cancer (NSCLC) in patients with non-resistant epidermal growth factor receptor (EGFR) mutations. Afatinib is also approved for the treatment of metastatic squamous NSCLC following progression on platinum-based chemotherapy. Common afatinib-associated toxicities include gastrointestinal and dermatologic events, which can be dose limiting. OBJECTIVES: In this review, the authors describe clinical trial experiences with afatinib, as well as best practices and practical approaches to the management of afatinib-associated adverse events in EGFR mutation-positive NSCLC. METHODS: Safety and tolerability data from phase 3 trials of afatinib were reviewed, together with real-life experiences from the authors' clinical practices. FINDINGS: Patient education, combined with early assessment and effective management of afatinib-related adverse events as well as dose- reduction strategies, allows patients to continue treatment and maximize the clinical benefits of afatinib.
BACKGROUND: Afatinib is an oral, irreversible ErbB family blocker indicated for first-line treatment of metastatic non-small cell lung cancer (NSCLC) in patients with non-resistant epidermal growth factor receptor (EGFR) mutations. Afatinib is also approved for the treatment of metastatic squamous NSCLC following progression on platinum-based chemotherapy. Common afatinib-associated toxicities include gastrointestinal and dermatologic events, which can be dose limiting. OBJECTIVES: In this review, the authors describe clinical trial experiences with afatinib, as well as best practices and practical approaches to the management of afatinib-associated adverse events in EGFR mutation-positive NSCLC. METHODS: Safety and tolerability data from phase 3 trials of afatinib were reviewed, together with real-life experiences from the authors' clinical practices. FINDINGS: Patient education, combined with early assessment and effective management of afatinib-related adverse events as well as dose- reduction strategies, allows patients to continue treatment and maximize the clinical benefits of afatinib.
Entities:
Keywords:
adverse events; afatinib; dose reduction; non-small cell lung cancer
Authors: Keunchil Park; Eng-Huat Tan; Ken O'Byrne; Li Zhang; Michael Boyer; Tony Mok; Vera Hirsh; James Chih-Hsin Yang; Ki Hyeong Lee; Shun Lu; Yuankai Shi; Sang-We Kim; Janessa Laskin; Dong-Wan Kim; Catherine Dubos Arvis; Karl Kölbeck; Scott A Laurie; Chun-Ming Tsai; Mehdi Shahidi; Miyoung Kim; Dan Massey; Victoria Zazulina; Luis Paz-Ares Journal: Lancet Oncol Date: 2016-04-12 Impact factor: 41.316
Authors: Mario E Lacouture; Dirk Schadendorf; Chia-Yu Chu; Martina Uttenreuther-Fischer; Uz Stammberger; Dennis O'Brien; Axel Hauschild Journal: Expert Rev Anticancer Ther Date: 2013-03-18 Impact factor: 4.512
Authors: R Califano; N Tariq; S Compton; D A Fitzgerald; C A Harwood; R Lal; J Lester; J McPhelim; C Mulatero; S Subramanian; A Thomas; N Thatcher; M Nicolson Journal: Drugs Date: 2015-08 Impact factor: 9.546
Authors: Rasha S Elbatanony; Vineela Parvathaneni; Nishant S Kulkarni; Snehal K Shukla; Gautam Chauhan; Nitesh K Kunda; Vivek Gupta Journal: Drug Deliv Transl Res Date: 2021-06 Impact factor: 5.671